1. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
- Author
-
Mundada, Nidhi S, Rojas, Julio C, Vandevrede, Lawren, Thijssen, Elisabeth H, Iaccarino, Leonardo, Okoye, Obiora C, Shankar, Ranjani, Soleimani-Meigooni, David N, Lago, Argentina L, Miller, Bruce L, Teunissen, Charlotte E, Heuer, Hillary, Rosen, Howie J, Dage, Jeffrey L, Jagust, William J, Rabinovici, Gil D, Boxer, Adam L, and La Joie, Renaud
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Alzheimer's Disease ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Acquired Cognitive Impairment ,Neurosciences ,Aging ,Behavioral and Social Science ,Dementia ,Biomedical Imaging ,Brain Disorders ,Clinical Research ,Neurodegenerative ,Neurological ,Humans ,Female ,Middle Aged ,Aged ,Male ,Retrospective Studies ,Amyloidogenic Proteins ,Alzheimer Disease ,Cognitive Dysfunction ,Alzheimer's disease ,MCI ,Tau-PET ,MRI ,Plasma biomarkers ,Alzheimer’s disease ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundPlasma phosphorylated tau (p-tau) has emerged as a promising biomarker for Alzheimer's disease (AD). Studies have reported strong associations between p-tau and tau-PET that are mainly driven by differences between amyloid-positive and amyloid-negative patients. However, the relationship between p-tau and tau-PET is less characterized within cognitively impaired patients with a biomarker-supported diagnosis of AD. We conducted a head-to-head comparison between plasma p-tau217 and tau-PET in patients at the clinical stage of AD and further assessed their relationships with demographic, clinical, and biomarker variables.MethodsWe retrospectively included 87 amyloid-positive patients diagnosed with MCI or dementia due to AD who underwent structural MRI, amyloid-PET (11C-PIB), tau-PET (18F-flortaucipir, FTP), and blood draw assessments within 1 year (age = 66 ± 10, 48% female). Amyloid-PET was quantified in Centiloids (CL) while cortical tau-PET binding was measured using standardized uptake value ratios (SUVRs) referenced against inferior cerebellar cortex. Plasma p-tau217 concentrations were measured using an electrochemiluminescence-based assay on the Meso Scale Discovery platform. MRI-derived cortical volume was quantified with FreeSurfer. Mini-Mental State Examination (MMSE) scores were available at baseline (n = 85) and follow-up visits (n = 28; 1.5 ± 0.7 years).ResultsPlasma p-tau217 and cortical FTP-SUVR were correlated (r = 0.61, p
- Published
- 2023